Polyethylene glycol (PEG) has become a foundational excipient and functional polymer in modern medicine. Emerging clinical evidence indicates that PEG itself – not only the active drug component – can act as a direct allergen in sensitized individuals. By identifying PEG-specific IgE responses, LLT’s technology provides a practical path to improved patient risk assessment, better investigation of unexplained allergic reactions, and more informed safety evaluation of PEG-containing therapeutics.

What Is PEG IgE Detection Kit?

LLT’s PEG IgE Detection Kit is an immunoassay-based solution designed to detect IgE antibodies directed against polyethylene glycol. The kit is built on LLT’s patented FocalTuning(TM) immunoassay platform, which uses two-level background correction to improve signal clarity and reduce the risk of false-positive and false-negative results.

Resolving the Diagnostic Gap in Idiopathic Anaphylaxis

Idiopathic anaphylaxis accounts for up to 10% of all anaphylaxis cases. For these patients, standard clinical evaluation does not identify a clear trigger, leaving physicians and patients without a reliable explanation, avoidance strategy, or risk-reduction plan. PEG sensitization represents an important blind spot because PEG may be hidden in medications, biologics, vaccines, bowel preparations, and other medical products. The PEG IgE Detection Kit can help clarify selected cases currently classified as idiopathic by identifying anti-PEG IgE as a possible underlying mechanism.

Supporting Safety of PEGylated and LNP Therapeutics

PEGylated and LNP therapeutics are increasingly important across modern drug development. For PEG-containing drug developers and pharmaceutical companies, PEG-related hypersensitivity is a development, clinical, regulatory, and post-market safety risk. A sensitive PEG IgE detection approach gives developers a stronger tool for understanding immune risk earlier and more precisely.